Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Nov. 9 — Robert Califf, President Barack Obama's nominee to lead the FDA, will get a confirmation hearing before the Senate Health, Education, Labor and Pensions Committee Nov. 17, a committee aide told Bloomberg BNA Nov. 9.
Califf, the deputy commissioner for medical products and tobacco at the agency and a former Duke University researcher, was nominated for the position in September (179 HCDR, 9/16/15).
The hearing will occur despite an announcement from Sen. Ben Sasse (R-Neb.) in October that he would block all HHS nominees from reaching the Senate floor until the administration explains the failures of the Affordable Care Act's CO-OP program.
Califf isn't expected to face much opposition in the committee, but Sasse's objection would make him unable to be considered by the full Senate, a requirement to getting confirmed. When Califf was nominated, Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) made note of Califf's “impressive credentials” and said the committee would “move promptly to consider his nomination.”
Califf would succeed former FDA Commissioner Margaret Hamburg, who stepped down at the end of March. Stephen Ostroff, the agency's former chief scientist, has served as acting commissioner since then. When Califf was appointed deputy commissioner, it was widely assumed he would be the nominee to permanently replace Hamburg. Califf's job as a researcher and professor at Duke has been on hold since he joined the FDA.
To contact the reporter on this story: Nathaniel Weixel in Washington at email@example.com
To contact the editor responsible for this story: Nancy Simmons at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)